June Lee, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, DavisM.D.1992School of Medicine
    Johns Hopkins UniversityB.S.1988Chemistry

    Collapse Overview 
    Collapse Overview
    June Lee, MD, is a Professor in the School of Medicine at UCSF. She was the chief architect of the highly successful Clinical and Translational Science Institute's Catalyst Program which serves as an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. She also oversaw key strategic partnerships at UCSF to include industry collaborations. She also served as Chair of the Drug, Device, Discovery and Development (D4) workgroup of UC BRAID (University of California Biomedical Research Acceleration Integration and Development) and was previously the Vice-Chair of CTSA Translational Key Function Committee.

    Prior to UCSF, she worked at Genentech where as the therapeutic area head, she led early clinical development programs in Infectious Diseases, Cardiovascular/Metabolic Diseases, and Respiratory Diseases. In that role, she was responsible for the clinical strategy and execution of programs in the early clinical development stages and successfully developed pre-clinical and late stage research projects in a variety of therapeutic areas through IND clearance and early stage clinical proof of concept studies.

    Collapse Research 
    Collapse Research Activities and Funding
    Carbohydrate-based Therapy for Lung Disease
    NIH/NHLBI P01HL128191Sep 1, 2016 - Jul 31, 2021
    Role: Co-Investigator
    Gene Regulation by IL-4 and IL-13 in Airway Cells
    NIH/NHLBI K08HL068591Jan 14, 2002 - Nov 30, 2006
    Role: Principal Investigator
    NIH/NHLBI F32HL009961Dec 30, 1998
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014 Jan; 44(1):38-46. PMID: 24131304; PMCID: PMC4204278.
    2. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin a: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012 Jan 08; 14(1):R6. PMID: 22225620.
      View in: PubMed
    3. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2008 Sep; 101(3):256-63. PMID: 18814448.
      View in: PubMed
    4. Campbell JD, Borish L, Haselkorn T, Rasouliyan L, Lee JH, Wenzel SE, Sullivan SD. The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. Eur Respir J. 2008 Nov; 32(5):1237-42. PMID: 18684845.
      View in: PubMed
    5. Peters AT, Klemens JC, Haselkorn T, Weiss ST, Grammer LC, Lee JH, Chen H. Insurance status and asthma-related health care utilization in patients with severe asthma. Ann Allergy Asthma Immunol. 2008 Apr; 100(4):301-7. PMID: 18450113.
      View in: PubMed
    6. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007 Dec; 132(6):1882-9. PMID: 18079222.
      View in: PubMed
    7. Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, Lee JH. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007 May; 119(5):1156-63. PMID: 17397912.
      View in: PubMed
    8. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007 Mar; 101(3):481-9. PMID: 16914299.
      View in: PubMed
    9. Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H, Wenzel SE, Weiss ST. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J. 2006 Dec; 28(6):1145-55. PMID: 16870656.
      View in: PubMed
    10. Lee JH, Haselkorn T, Chipps BE, Miller DP, Wenzel SE. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. J Asthma. 2006 Apr; 43(3):179-84. PMID: 16754518.
      View in: PubMed
    11. Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006 Mar; 96(3):406-14. PMID: 16597074.
      View in: PubMed
    12. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ, Sheppard D. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol. 2001 Oct; 25(4):474-85. PMID: 11694453.
      View in: PubMed
    13. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, Farese RV, Sheppard D. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol. 2000 Jul; 20(14):5208-15. PMID: 10866676; PMCID: PMC85969.